MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression


Lack of eradication of disseminated breast cancer by chemotherapy is a central clinical problem. Even tumors that show substantial shrinkage after drug treatment frequently relapse and eventually become refractory to all drugs available. The mechanisms underlying this lack of eradication are largely undefined and it is therefore difficult to develop curative strategies using systemic anti-cancer therapy. In a recent article low DUSP4 expression was reported to activate RAS-ERK signaling in residual breast cancer after neoadjuvant chemotherapy. This may be a druggable characteristic because MEK inhibition increases docetaxel sensitivity in a xenograft model.

More about this publication

Breast Cancer Research: BCR
  • Volume 14
  • Issue nr. 6
  • Pages 324

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.